Biotech firm Prothena misses revenue targets but gets a "buy" rating despite quarterly losses.

Biotech firm Prothena (NASDAQ: PRTA) beat Q3 EPS estimates but missed revenue targets, with revenue down 98.9% year-over-year. Despite a negative net margin and return on equity, HC Wainwright reiterates a "buy" rating with an $84.00 price target, indicating a 370.85% potential upside. Prothena focuses on therapies for protein dysregulation-related diseases like Alzheimer's and Parkinson's. Shares traded at $17.84 on Wednesday.

November 13, 2024
4 Articles

Further Reading